logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10934274 B1

PDFFull Text
Date of Patent:
Mar. 02, 2021

Filed:

Apr. 14, 2016

Quinoline derivatives as tam rtk inhibitors

Applicants:

Qurient Co., Ltd., Gyeonggi-do, KR;

Lead Discovery Center Gmbh, Dortmund, DE;

Inventors:

Kiyean Nam, Gyeonggi-do, KR;

Jaeseung Kim, Seoul, KR;

Seohyun Ahn, Gyeonggi-do, KR;

Yeejin Jeon, Gyeonggi-do, KR;

Doohyung Lee, Seoul, KR;

Dongsik Park, Gyeonggi-do, KR;

Young-In Yang, Gyeonggi-do, KR;

SaeYeon Lee, Gyeonggi-do, KR;

Jeongjun Kim, Seoul, KR;

Jiye Ahn, Gyeonggi-do, KR;

Hana Kim, Gyeonggi-do, KR;

Chun-won Jung, Gyeonggi-do, KR;

Carsten Schultz-Fademrecht, Dortmund, DE;

Assignees:

QURIENT CO., LTD., Gyeonggi-Do, KR;

LEAD DISCOVERY CENTER GMBH, Dortmund, DE;

Attorney:

Saliwanchik, Lloyd & Eisenschenk

Primary Examiner:

Rebecca L Anderson

Int. Cl.
CPC ...
C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01); A61P 35/02 (2006.01); A61P 35/04 (2006.01); A61P 35/00 (2006.01); A61K 31/4709 (2006.01); A61K 31/497 (2006.01); A61K 31/501 (2006.01); A61K 31/506 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07D 401/14 (2013.01); A61K 31/4709 (2013.01); A61K 31/497 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); A61P 35/04 (2018.01); C07D 401/12 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01);
Abstract

The present invention relates to novel compounds which are inhibitors of TAM (Axl, Mer and Tyro 3) and/or Met family receptor tyrosine kinases (RTKs). These compounds are suitable for the treatment of disorders associated with, accompanied by, caused by or induced by a receptor of the TAM family, in particular a hyperfunction thereof. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly immune-suppressive cancer, refractory cancer and cancer metastases.

Find Patent Forward Citations

Loading…